Cell-free Enzymatic DNA Synthesis to enable synthetic biology

Purpose and goal:

Moligo is a DNA synthesis company producing long single stranded DNA oligonucleotides (ssDNA) with unprecedented purity, length and scale through an enzyme-based proprietary approach. With the support of Vinnova funding, Moligo will develop new DNA based technologies for the synthesis of longer and more complex DNA sequences, enabling the development of new therapeutics and new applications in synthetic biology.

Expected results and effects:

The project´s success will be pivotal for expanding our business, freeing us from reliance on other international double-stranded DNA suppliers. This will shorten the development time for our clients to reach clinical trials, where they need 1000 times more of our DNA products. With the implementation of this project, Moligo Technologies will become a key global supplier of high quality synthetic DNA, a partner of choice for the largest biotech and pharma companies.

Approach and implementation:

Moligo will develop an in-house, fast and cost-effective DNA assembly technology for the synthesis of long, complex double-stranded DNA molecules through the following technical implementation steps: (i) development of a DNA assembly algorithm, (ii) synthesis and assembly of DNA sequences obtained through the algorithm (iii) cloning-free of full and accurate assembly in milligram scale, (iv) in vitro assembly of real case sequences for mRNA production templates and long therapeutic genes for cell and gene therapy.